<?xml-stylesheet type="text/xsl" href="https://emersonexchange365.com/cfs-file/__key/system/syndication/rss.xsl" media="screen"?><rss version="2.0" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:slash="http://purl.org/rss/1.0/modules/slash/" xmlns:wfw="http://wellformedweb.org/CommentAPI/"><channel><title>Pharmaceutical and Biotech Automation Knowledge Exchange</title><link>/industries/lifesciences/b/life-sciences-blog/posts/pharmaceutical-and-biotech-automation-knowledge-exchange</link><description>The pharmaceutical and biopharmaceutical industries have been interpreting recent FDA draft guidance— Data Integrity and Compliance With CGMP Guidance —and exploring new areas such as continuous manufacturing. The Emerson Life Sciences team has a full</description><dc:language>en-US</dc:language><generator>Telligent Community 13</generator></channel></rss>